Identification and evaluation of a panel of serum biomarkers for predicting response to thalidomide in multiple myeloma patients

Expert Review of Proteomics

Volumn 8, Issue 4, 2011, Pages 439-442

  Xiong, Qian ^a   Ge, Feng ^a  

^a INSTITUTE OF HYDROBIOLOGY   (China)

Author keywords

2D DIGE; multiple myeloma; predictive biomarkers; thalidomide

Indexed keywords

THALIDOMIDE; TUMOR MARKER;

ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; LIQUID CHROMATOGRAPHY; MAJOR CLINICAL STUDY; MULTIPLE MYELOMA; PREDICTION; PROTEIN EXPRESSION; PROTEOMICS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; TREATMENT RESPONSE; TWO DIMENSIONAL DIFFERENCE GEL ELECTROPHORESIS;

EID: 80051733448     PISSN: 14789450     EISSN: 17448387     Source Type: Journal    
DOI: 10.1586/epr.11.42     Document Type: Article

References (10)

1. Rajpal R, Dowling P, Meiller J et al. A novel panel of protein biomarkers for predicting response to thalidomide-based therapy in newly diagnosed multiple myeloma patients. Proteomics 11(8), 1391-1402 (2011). Excellent research article on proteomics-based identification of predictive biomarkers.
2. Cavallo F, Boccadoro M, Palumbo A. Review of thalidomide in the treatment of newly diagnosed multiple myeloma. Ther. Clin. Risk Manag. 3(4), 543-552 (2007). (Pubitemid 47496958)
3. Gao Y, Holland RD, Yu LR. Quantitative proteomics for drug toxicity. Brief Funct. Genomic Proteomic 8(2), 158-166 (2009). Excellent review on quantitative proteomic technologies and their increasing applications in drug toxicity.
4. Chakravarti B, Mallik B, Chakravarti DN. Proteomics and systems biology: Application in drug discovery and development. Methods Mol. Biol. 662, 3-28 (2010).
5. Rabilloud T, Chevallet M, Luche S, Lelong C. Two-dimensional gel electrophoresis in proteomics: Past, present and future. J. Proteomics 73(11), 2064-2077 (2010).
6. Elliott MH, Smith DS, Parker CE, Borchers C. Current trends in quantitative proteomics. J. Mass Spectrom. 44(12), 1637-1660 (2009). Excellent review on the concept and application of quantitative proteomics.
7. De Bock M, de Seny D, Meuwis MA et al. Challenges for biomarker discovery in body fluids using SELDI-TOF-MS. J. Biomed. Biotechnol. 2010, 906082 (2010).
8. Yang L, Guo S, Li Y, Zhou S, Tao S. Protein microarrays for systems biology. Acta Biochim. Biophys. Sin. (Shanghai) 43(3), 161-171 (2011).
9. Tedford NC, Hall AB, Graham JR, Murphy CE, Gordon NF, Radding JA. Quantitative analysis of cell signaling and drug action via mass spectrometry-based systems level phosphoproteomics. Proteomics 9(6), 1469-1487 (2009). Excellent review on the application of phosphoproteomics analysis to drug toxicology.
10. Tian Y, Zhang H. Glycoproteomics and clinical applications. Proteomics Clin. Appl. 4(2), 124-132 (2010).